寡转移性非鳞状非小细胞肺癌巩固性局部治疗的成本效果分析
该研究从瑞士医疗支付方视角构建马尔可夫模型,比较局部治疗与单纯维持化疗在寡转移性非鳞状非小细胞肺癌中的成本效果,模型参数基于一项II期试验(NCT01725165)和一项近期III期试验。结果显示局部治疗可增加0.24个质量调整生命年、额外花费9641瑞士法郎,增量成本效果比为每获得1个质量调整生命年40972瑞士法郎。作者认为对于一线全身治疗有应答的经选择寡转移性非小细胞肺癌患者,局部治疗可能具有成本效果。
要点
- 模型无进展生存期:维持化疗3.8个月,局部治疗11.4个月;总生存期两组均为15.5个月。
- 局部治疗增加0.24个质量调整生命年,额外成本9641瑞士法郎,增量成本效果比40972瑞士法郎/质量调整生命年。
- 概率敏感性分析中,在每质量调整生命年100000瑞士法郎的支付意愿阈值下,61.7%的模拟中局部治疗占优或具有成本效果。
核心结论
- 对于一线全身治疗有应答的经选择寡转移性非小细胞肺癌患者,局部治疗可能具有成本效果。
研究设计与样本
- 从瑞士医疗支付方视角构建马尔可夫模型,比较局部治疗与维持化疗在寡转移性非小细胞肺癌中的成本效果。
- 治疗方案与无进展生存期参数基于一项II期试验(NCT01725165),总生存期参数基于一项近期III期试验,效用值取自已发表数据。
主要发现
- 模型无进展生存期为维持化疗3.8个月 vs 局部治疗11.4个月(试验中分别为3.9个月和11.9个月)。
- 模型总生存期两组均为15.5个月。
- 局部治疗增加0.24个质量调整生命年,额外成本9641瑞士法郎,增量成本效果比为每获得1个质量调整生命年40972瑞士法郎。
- 概率敏感性分析显示,在每质量调整生命年100000瑞士法郎的支付意愿阈值下,61.7%的模拟中局部治疗占优或具有成本效果。
临床怎么用
- 作者认为对于一线全身治疗有应答的经选择寡转移性非小细胞肺癌患者,局部治疗可能具有成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel systemic therapies have improved the prognosis of metastatic non-small cell lung cancer (NSCLC), but costs of some of these drugs are a matter of ongoing debate. More recently, local therapies (LT) such as radiotherapy and surgery have been suggested as additional treatment in oligometastatic NSCLC demonstrating an improved progression-free survival (PFS) in a phase II trial compared to maintenance chemotherapy (MC) alone. The aim of this analysis was to assess the cost-effectiveness of local therapies in oligometastatic NSCLC. METHODS: We constructed a Markov model comparing the cost-effectiveness of LT versus MC for oligometastatic NSCLC from the Swiss healthcare payer's perspective. Treatment specifications and PFS were based on the phase II trial (NCT01725165). Overall survival (OS) was inferred from a recent phase III trial. Utilities were taken from published data. Primary outcome was the incremental cost-effectiveness-ratio (ICER, costs in Swiss Francs (CHF) per quality-adjusted life-year (QALY) gained). RESULTS: PFS in the model was 3.8 months for MC and 11.4 months for LT (compared to 3.9 months and 11.9 months in the trial). OS in the model was 15.5 months in both arms. LT was cost-effective with a gain of 0.24 QALYs at an additional cost of CHF 9641, resulting in an ICER of CHF 40,972/QALY gained. Probabilistic sensitivity analyses demonstrated that LT was dominant or cost-effective at a willingness-to-pay threshold of CHF 100,000 per QALY in 61.7% of the simulations. CONCLUSIONS: LT may be cost-effective for selected patients with oligometastatic NSCLC responding to first-line systemic therapy.
引用
- Panje CM, Dedes KJ, Matter-Walstra K, et al. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiother Oncol. 2018. PMID: 30104008. doi:10.1016/j.radonc.2018.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。